BNET Industries
Last Fiscal Year Sales:$1.0B
- Private
- US
Dow Jones Description
Injectable Monoclonal Antibody-Based Pharmaceuticals Mfr & Developer for Cardiovascular, Infectious & Autoimmune Diseases
CFO & Vice President
Richard A. BierlyNumber of Employees 3,000
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
Litigator of the Week: Dianne Elderkin of Woodcock Washburn
News & Analysis
Filter by
centocor inc. - All News and Analysis
Ustekinumab approval delayed by FDA
- 2009-02-01
The Food and Drug Administration has requested more information about ustekinumab before it is approved for treating moderate to severe plaque psoriasis, according to Centocor Inc., the manufacturer of the monoclonal antibody. In a statement issued in December, the company reported that the information requested by the FDA includes...
Seminar in advanced rheumatology: selected proceedings of a live symposium held March, 2008 bulletin of the NYU hospital for joint diseases
- 2008-09-01
Supported by educational grants from: Amgen & Wyeth Pharmaceuticals; Bristol-Myers Squibb; Centocor, Inc.; Genentech/Biogen IDEC; Roche Laboratories Target Audience This program is intended for physicians and allied healthcare professionals in the fields of rheumatology, orthopedics and internal medicine. Statement of Need New therapies are available for...
Research and Markets: Available Now: Thought Leader Insight & Analysis: Psoriasis
- 2008-05-28
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c93073) has announced the addition of "Thought Leader Insight & Analysis: Psoriasis" to their offering. Psoriasis Thought Leader Panel #13 continues the researcher's discussion with US and European Thought Leaders. During these conversations the Panelists offered their insight into the following: -...
Centocor joins its parent company in blogosphere
- 2008-04-01
CENTOCOR LAUNCHED itself into the blogosphere with the debut of its corporate blog at cnto411.com. Melissa Katz, a Centoco spokeswoman, told MM&M the corporate blog aims to serve as a forum for discussion on issues relevant to the industry and not a platform for sounding off on Centocor products. "I...
Centocor and ustekinumab
- 2008-04-01
Centocor, Inc recently announced that its Biologics License Application BLA for ustekinumab (CNTO 1275) has been accepted for filing by the FDA for the treatment of chronic moderate to severe plaque psoriasis in adult patients. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23)....
Psunrise: prospective study using remicade in psoriasis patients with an inadequate response to etanercept
- 2008-04-01
Sponsored by Centocor Inc. The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least 4 months, without enough improvement in their psoriasis symptoms.Condition Intervention...
Endo acts quickly to name CEO: David Holveck
- 2008-03-13
Acting swiftly to replace its departed chief executive officer, Endo Pharmaceuticals Holdings Inc. yesterday named pharmaceutical veteran David P. Holveck to lead the Chadds Ford drugmaker. Holveck, 62, who lives in Ambler and retired March 1 as president of Johnson & Johnson Development Corp., made a name for himself in...
Endo Pharmaceuticals Names David P. Holveck President and Chief Executive Officer
- 2008-03-12
Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) today announced that David P. Holveck has been named President, Chief Executive Officer and a Director of the company, effective April 1, 2008. Mr. Holveck was most recently President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson &...
MEASURING THE SIGNAL
- 2008-03-01
There is no point in running a great journal ad if no one notices it. But how do you truly determine if the signal is cutting through the noise? Stephen Hellebusch tests the theory of signal detectability on a group of primary care physicians When an advertisement is...
Prospective study using remicade in psoriasis patients with an inadequate response to etanercept
- 2008-03-01
Sponsored by: Centocor, Inc. The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least 4 months, without enough improvement in their psoriasis symptoms.Condition Intervention...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Richard A. Bierly | CFO & Vice President |
| Daniel Everitt | Vice President of Clinical Pharmacology and Global Pharmacovigilance |
| Ronald E. Schmid | Vice President, Corp Communications |
| William R Tolbert | Vice President |
| David P. Holveck | Director |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | CFO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President of Clinical Pharmacology and Global Pharmacovigilance | Current |
| Institute for Oneworld Health | Board of Directors | Current |
| SmithKline Beecham Corporation | Director of Clinical Pharmacology | Former |
| Neuroscience, Inc | Group Director | Former |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President, Corp Communications | Current |
| Organization | Position | Status |
|---|---|---|
| Advanced Tissue Sciences, Inc. | Vice President | Current |
| Centocor, Inc. | Vice President | Current |
| Invitron Limited | Vice President | Current |
| Merchant-Taylor International, Inc | Senior Associate | Current |
David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo in April 2008. Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson since 2004. Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc., at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council as well as the Board of Directors of Light Sciences Oncology, Inc.
| Organization | Position | Status |
|---|---|---|
| Endo Pharmaceuticals Holdings Inc. | President & Chief Executive Officer | Current |
| Johnson & Johnson Development Corp. | Vice President, Corporate Development | Current |
| Tengion, Inc. | Current | |
| Biotechnology Industry Organization | board member | Current |
| Eastern Technology Council | Board Member | Current |
| Centocor, Inc. | Director | Current |
| University City Science Center | Board of Directors | Current |
| Light Sciences Oncology, Inc. | Board of Directors | Current |
| Liberty Science Center, Inc. | Board Member | Current |
| Endo Pharmaceuticals Holdings Inc. | Board of Directors | Current |
| Centocor, Inc. | Chief Executive Officer | Former |
| Johnson & Johnson | President, Corporate Development | Former |
| Centocor, Inc. | president | Former |
| Centocor, Inc. | chief operating officer | Former |
| General Electric Company | Team Member | Former |
| Abbott Laboratories | Team Member | Former |
| Corning Glass Works | Team Member | Former |
| Johnson & Johnson Development Corp. | President | Former |
| The Group Inc. | Chairman | Former |
| Johnson & Johnson Development Corp. | Company Group Chairman | Former |
| Johnson & Johnson | Company Group Chairman | Former |
| West Chester University | B.S. Degree In Education | Former |
Executive News
-
Endo Pharmaceuticals Introduces Valstar (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
FDA extends review on Endo drug
-
Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment 9/3/2009
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive...
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate...
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
-
FDA taking more time to review Endo hypogonadism drug
-
Endo partners with ProStrakan to market testosterone transdermal gel
-
Endo to commercialize Fortesta in the U.S.
-
Endo licenses ProStrakan's testosterone gel Fortesta in US for up to $210 million
-
Endo buys rights to ProStrakan testosterone replacement gel Fortesta
-
Endo In Deal To Sell ProStrakan's Testosterone Gel In US
-
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
-
Biotech 2009 to Feature Endo Pharmaceuticals President and CEO, David P. Holveck, as Dinner...
-
Endo Pharmaceuticals's COO resigns
-
Endo Pharmaceuticals (ENDP) Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
Glass Door
Centocor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
